Pfizer, breast cancer and Arvinas

Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints
Pfizer Inc.’s next-generation treatment for breast cancer posted mixed results in a final-stage study, a potential setback for a drug the company once called a blockbuster in the making.
Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug
Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming late-stage trial data for vepdegestrant, an experimental breast cancer therapy it co-develops with Pfizer (NYSE:PFE).
Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results
An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients lived without the disease worsening, but failed to achieve statistically significant results in others in a late-stage study.
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend progression-free survival (PFS) in certain patients in a Phase III trial.
Pfizer, Arvinas post mixed late-stage trial results for breast cancer therapy (update)
Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug vepdegestrant. Read more here.
Pfizer-Arvinas' breast cancer treatment shows mixed results in late-stage study
Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of patients in a late-stage trial, sending the Connecticut-based biotech's shares down 36% before the bell.
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug.
Fierce Pharma16h
Senators expand probe of Pfizer, Lilly DTC platforms to include telehealth provider partners
In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...
STAT2d
Telehealth platforms in senators’ crosshairs over relationship with Eli Lilly, Pfizer
Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.
Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators (CORRECTED)
Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...
BioPharma Dive3d
Arvinas gets positive breast cancer data, but finds differentiation a hard sell
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...
STAT1d
Pharmalittle: We’re reading about senators probing telehealth, Boston’s slumping biotech hub and more
The Maryland Senate voted to allow a state board to extend its mandate for lowering prescription drug costs to all residents.
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...
Posts falsely claim Pfizer published list of Covid-19 vaccine side effects
Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...
Becker's Hospital Review1d
10 drugs poised to be best-sellers in 2026
The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.